Patents

Scientific and applicative expertise is highlighted by more than 200 international published papers and more than 30 international patent grants, as well as by different research and development projects developed and managed by the founding partners.

PATENTS

EP2292639: Tubulysin derivatives as anticancer drugs
Date of publication and mention of the patent grant: 03/09/2014.

US8580820: Tubulysin compounds with high cytotoxicity, pharmaceutical compounds thereof, and method of use thereof
Date of patent: 12/11/2013.

IT1394860: Derivati delle tubulisine
Date of patent: 20/07/2012.

PATENT APPLICATIONS

CA2710693: Pharmaceutical compositions (Tubulysin derivative formulations)
Filing date: 21/07/2010.

JP2011/037846: Pharmaceutical compositions (Tubulysin derivative formulations)
Filing date: 24/02/2011.

EP2789619: Pharmaceutical compounds with angiogenesis inhibitory activity
Filing date: 04/04/2014.

US2014/343294: Pharmaceutical compounds (antiangiogenic compunds)
Filing date: 10/04/2014.

CA2848779: Pharmaceutical compounds (antiangiogenic compunds)
Filing date: 11/04/2014.

IT2013MI00602: Composti farmaceutici (composti antiangiogenici)
Filing date: 12/04/2013.

IT2014MI00297: Composti farmaceutici (composti antiangiogenici)
Filing date: 27/02/2014.

LICENSING/SALE of KemoTech’s PATENTS

KemoTech Srl intends to license or sale the proprietary patents and patent applications to third parties.
Experimental data concerning the platforms (products, processes, uses) developed by KemoTech are available and they can be supplied upon specific request.